See more : Holiday Island Holdings, Inc. (HIHI) Income Statement Analysis – Financial Results
Complete financial analysis of Ambrx Biopharma Inc. (AMAM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ambrx Biopharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Stalprodukt S.A. (STP.WA) Income Statement Analysis – Financial Results
- Finsbury Growth & Income Trust PLC (FGT.L) Income Statement Analysis – Financial Results
- Hill International, Inc. (HIL) Income Statement Analysis – Financial Results
- Advanced Blockchain AG (BWQ.DE) Income Statement Analysis – Financial Results
- Marubeni Corporation (8002.T) Income Statement Analysis – Financial Results
Ambrx Biopharma Inc. (AMAM)
About Ambrx Biopharma Inc.
Ambrx Biopharma Inc., a clinical-stage biologics company, discovers and develops engineered precision biologics using its proprietary expanded genetic code technology platform. Its lead product candidate is ARX788, an anti-HER2 antibody-drug conjugate (ADC), which is investigated in various clinical trials for the treatment of breast cancer, gastric/gastroesophageal junction cancer, and other solid tumors, including ongoing Phase 2/3 clinical trials for the treatment of HER2-positive metastatic breast cancer and gastric cancer. The company is also developing two earlier-stage product candidates, including ARX517, an anti-PSMA ADC, which is in a Phase 1 clinical trial for the treatment of prostate cancer and other solid tumors; and ARX305, an anti-CD70 ADC in investigational new drug-enabling studies for the treatment of renal cell carcinoma and other cancers. In addition, it is developing other multiple product candidates targeting immuno-oncology applications, which include ARX822, a fab-small molecule bispecific that is in preclinical development for cancers; and ARX102, an immuno-oncology IL-2 pathway agonist to stimulate the patient's own immune system by targeting the ß and gamma receptors on the cytotoxic T cell. Ambrx Biopharma Inc. has collaborations with Bristol Myers Squibb Company; AbbVie Inc.; BeiGene; Sino Biopharmaceutical Co., Ltd.; NovoCodex; and Elanco Animal Health. The company was incorporated in 2003 and is headquartered in La Jolla, California.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 7.40M | 7.46M | 13.67M | 10.31M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 7.40M | 7.46M | 13.67M | 10.31M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 53.31M | 54.81M | 20.43M | 26.38M |
| General & Administrative | 20.33M | 17.07M | 6.35M | 6.40M |
| Selling & Marketing | 2.73M | 0.00 | 0.00 | 0.00 |
| SG&A | 23.05M | 17.07M | 6.35M | 6.40M |
| Other Expenses | -2.22M | -3.86M | -4.75M | -38.00K |
| Operating Expenses | 74.14M | 71.88M | 26.79M | 32.78M |
| Cost & Expenses | -83.83M | 71.88M | 26.79M | 32.78M |
| Interest Income | 369.00K | 0.00 | 27.00K | 195.00K |
| Interest Expense | 968.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.29M | 2.15M | 1.94M | 2.05M |
| EBITDA | -55.79M | -62.27M | -11.17M | -20.42M |
| EBITDA Ratio | -753.69% | -835.28% | -81.72% | -198.03% |
| Operating Income | -57.08M | -64.42M | -13.12M | -22.47M |
| Operating Income Ratio | -771.16% | -864.17% | -95.93% | -217.94% |
| Total Other Income/Expenses | -18.98M | -3.86M | -4.72M | 157.00K |
| Income Before Tax | -76.06M | -68.29M | -17.84M | -22.32M |
| Income Before Tax Ratio | -1,027.55% | -915.99% | -130.48% | -216.42% |
| Income Tax Expense | 1.94M | 1.00K | 1.00K | -2.00K |
| Net Income | -78.00M | -68.29M | -17.84M | -22.31M |
| Net Income Ratio | -1,053.72% | -916.00% | -130.49% | -216.40% |
| EPS | -2.02 | -3.34 | -0.47 | -0.59 |
| EPS Diluted | -2.02 | -3.34 | -0.47 | -0.59 |
| Weighted Avg Shares Out | 38.61M | 20.45M | 37.67M | 37.67M |
| Weighted Avg Shares Out (Dil) | 38.61M | 20.45M | 37.67M | 37.67M |
Ambrx to Present at JMP Securities Life Sciences and RBC Capital Markets Global Healthcare Conferences
Seis principais fornecedores de equipamentos para bebidas artesanais se fundem em negócio de US$ 100 milhões para lançar o primeiro balcão exclusivo para todas as necessidades de bebidas artesanais
Ambrx to Present Preclinical Data on ARX517 and ARX305 at the 2023 AACR Annual Meeting
5 Best and Worst Performing Small-Cap Stocks in February 2023
Ambrx Raises $78 Million and Completes its ATM Program
Darwin Global Management Now Owns 26.4% of Ambrx Biopharma
Why Shares of Ambrx Biopharma Fell Tuesday
Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Ambrx to Commence Trading on Nasdaq
ACE-Breast-02 Pivotal Phase 3 Study of Ambrx’s ARX788 for the Treatment of HER2 Positive Metastatic Breast Cancer Achieves Positive Results
Source: https://incomestatements.info
Category: Stock Reports